The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy

Stopped Sponsor will amend study design by incorporating reconfirmation of coagulopathy following discussion with FDA regarding findings from SCARLET1 study.

Conditions

• Sepsis and Coagulopathy

Interventions

• DRUG: ART-123
• DRUG: Placebo Comparator - Placebo

Sponsor

Asahi Kasei Pharma America Corporation